# OnCo record nct03729245 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03729245/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03729245", "NCT03729245" ;
  schema:name "A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)"@en ;
  schema:description "A phase 3 trial of Bempegaldesleukin, Sunitinib, Nivolumab and Cabozantinib in Renal cell carcinoma, run by Nektar Therapeutics, recorded as terminated on the registry."@en ;
  schema:url <https://onco.cc/trials/nct03729245/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03729245> ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/rcc/> ;
  onco:drugs <https://onco.cc/drugs/bempegaldesleukin/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/cabozantinib/> ;
  onco:companies <https://onco.cc/companies/nektar-therapeutics/> .